Bloomberg News

Two Novartis Drugs Win Backing in Final U.K. Leukemia Guidance

April 24, 2012

Novartis AG (NOVN)’s Tasigna and Glivec drugs won the backing of the U.K.’s health-cost agency for use against a rare blood cancer in final treatment guidelines.

The National Institute for Health and Clinical Excellence rejected a competing product, Bristol-Myers Squibb Co. (BMY:US)’s Sprycel, for use in patients with chronic myeloid leukemia, the agency said in a statement today. The agency advises the National Health Service on which medicines represent value for money.

Novartis offered a price cut that allowed a recommendation for Tasigna, and the Basel, Switzerland-based company asked that the discount be kept confidential, the agency said.

To contact the reporter on this story: Kristen Hallam in London at

To contact the editor responsible for this story: Phil Serafino at

Burger King's Young Buns

(enter your email)
(enter up to 5 email addresses, separated by commas)

Max 250 characters

Companies Mentioned

  • BMY
    (Bristol-Myers Squibb Co)
    • $51.01 USD
    • 1.21
    • 2.37%
Market data is delayed at least 15 minutes.
blog comments powered by Disqus